| 摘要 |
The invention relates to quinazoline derivatives of formula (I) wherein m is an integer from 1 to 2; R<1 >represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or -NR<5>R<6 >(wherein R<5 >and R<6>, which may be the same or different, each represents hydrogen or C1-3alkyl), R<2 >represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R<3 >represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro, X<1 >represents -O-, -CH2-, -S-, -SO-, -SO2-, -NR<7>CO-, -CONR<8>-, -SO2NR<9>-, -NR<10>SO2- or -NR<11>- (wherein R<7>, R<8>, R<9>, R<10 >and R<11 >each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R<4 >represents an optionally substituted 5 or 6 membered saturated carbocyclic or hetrocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
|
